BTIG reiterates Uber Buy rating after Delivery Hero bid

BTIG reaffirms Uber Buy rating with $100 target after Delivery Hero bid. Stock seen as undervalued.

Today / 10:31|Last updated: Today / 10:33

BTIG reiterated a Buy rating and $100 price target on Uber after reports of a bid for Delivery Hero shares.

Uber offered €33 per share for Delivery Hero's remaining shares, but the bid was reportedly rejected. BTIG estimates low single-digit EPS dilution from the deal.

Uber shares trade at $71.82. Analysts see undervaluation with a fair value estimate pointing to upside.

More News

Jefferies Raises SentinelOne Price Target to $24

Today / 11:03

631

Jefferies Raises SentinelOne Price Target to $24

Jefferies raised SentinelOne price target to $24 on margin outlook, maintaining Buy rating. Stock at $18.71, NNARR growth expected. Analyst sees H2 margin expansion.

ANALYST RATINGS →

Today / 11:02

566

ThinkEquity Initiates Atlas with Buy

ThinkEquity initiates Atlas Technical Consultants with a Buy rating and $15 target. The firm highlights the value of the Brazil critical-minerals option.

ANALYST RATINGS →

Today / 11:00

941

Reddit Stock Rating Boosted by App Growth

Citizens maintains Market Outperform on Reddit stock with $240 target. App installs surged 129% YoY, driving advertising growth.

ANALYST RATINGS →

Today / 10:33

492

Wolfe Research Reaffirms Ionis Stock Outperform Rating

Wolfe Research reiterates Outperform rating on Ionis Pharmaceuticals stock. Analysis of Arrowhead competition and financial results.

ANALYST RATINGS →

Today / 10:30

550

BTIG Reiterates Neutral on Affirm Stock

BTIG reiterates Neutral on Affirm stock amid credit trends. Analysis of delinquencies, growth prospects, and analyst targets.

ANALYST RATINGS →

Mizuho Cuts Intuit Target on TurboTax Weakness

Today / 10:02

707

Mizuho Cuts Intuit Target on TurboTax Weakness

Mizuho cuts Intuit target to $500 on TurboTax weakness; shares fall 20%. Read more on Bond.az.

ANALYST RATINGS →

Today / 08:00

677

Leerink Reaffirms Eli Lilly Stock Rating on Gene Therapy

Leerink reaffirms Eli Lilly stock rating with Outperform and $1,119 target, citing promising gene therapy data from VERVE-102 trial. Bond.az covers the latest.

ANALYST RATINGS →

Today / 06:02

602

Goldman Sachs Initiates Hemab Buy

Goldman Sachs initiates Hemab Therapeutics with buy rating. Sutacimig and HMB-002 target rare bleeding disorders.

ANALYST RATINGS →

Today / 06:01

425

Morgan Stanley Initiates Avalyn Pharma with Overweight

Morgan Stanley initiates Avalyn Pharma with Overweight rating and $53 target. The inhaled therapies AP01 and AP02 show promise in pulmonary fibrosis.

ANALYST RATINGS →

Today / 06:00

496

Goldman Sachs Backs Seaport Stock

Goldman Sachs initiates coverage on Seaport Therapeutics with an Early-Stage Biotech rating. Learn about the company's platform and financials.

ANALYST RATINGS →

Jefferies Initiates Avalyn Pharma with Buy

Yesterday / 15:32

644

Jefferies Initiates Avalyn Pharma with Buy

Jefferies initiates Avalyn Pharma with Buy rating and $52 price target. AP01 shows promising efficacy in progressive lung diseases.

ANALYST RATINGS →

Yesterday / 15:31

924

Jefferies Initiates Pershing Square USA Buy

Jefferies initiates Buy rating on Pershing Square USA (PSUS), highlighting the fund's strategy, discount, and lack of performance fee.

ANALYST RATINGS →

...